Here are the Form 4 insider transactions from BioLife Solutions Inc. (BLFS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BLFS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BLFS filings page.
BioLife Solutions Chief Marketing Officer Todd Berard reported equity compensation and related tax withholding in company stock. He received two grants of restricted common shares, one for 20,096 shares that vests 25% after one year and then in 12 quarterly installments, and another for 22,479 shares that vested at approximately 156% of the target grant based on the company’s total shareholder return versus selected peers from January 1, 2024 through December 31, 2025. In connection with the vesting of the market-based award, 8,846 shares were withheld at a price of $22.65 per share to cover tax obligations, leaving him with 166,293 common shares held directly after these transactions.
DuRoss Amy reported acquisition or exercise transactions in this Form 4 filing.
BioLife Solutions director Amy DuRoss received an award of 8,170 shares of Common Stock as restricted stock. The grant was made at no cash cost under the BioLife Solutions 2023 Performance Incentive Plan and will fully vest on the first anniversary of the vesting date of January 2, 2026. After this award, DuRoss directly holds 26,857 common shares.
BioLife Solutions Inc. Chief Financial Officer Troy Wichterman reported equity compensation and related tax withholding transactions in company stock. On February 24, 2026, he acquired 31,150 shares and 64,866 shares of restricted common stock at $0 per share as grants under the 2023 Omnibus Performance Incentive Plan.
The first grant vests 25% on the first anniversary of the grant date and then in 12 equal quarterly installments. The second grant vested at approximately 156% of the target number of shares based on total shareholder return from January 1, 2024 through December 31, 2025 versus a peer group. To cover tax withholding on the vested market-based award, 25,525 shares were disposed of at $22.65 per share. Following these transactions, Wichterman directly held 221,237 shares of common stock.
Hunt Anthony reported acquisition or exercise transactions in this Form 4 filing.
BioLife Solutions Inc. director Anthony Hunt received a grant of 8,170 shares of common stock as a restricted stock award. The award was made at no cash cost per share and increased his directly held common stock to 15,046 shares following the transaction. According to the footnote, the restricted stock was granted under the BioLife Solutions 2023 Performance Incentive Plan and "fully vests on the first anniversary of the vesting date of January 2, 2026."
Coste Catherine reported acquisition or exercise transactions in this Form 4 filing.
BioLife Solutions director Catherine Coste reported an equity award of 8,170 shares of common stock as a grant under the BioLife Solutions 2023 Performance Incentive Plan. The restricted stock was granted at no cash price and will fully vest on the first anniversary of the vesting date of January 2, 2026. Following this award, Coste beneficially owns 13,871 common shares directly.
Ellingson Rachel reported acquisition or exercise transactions in this Form 4 filing.
BioLife Solutions Inc. director Rachel Ellingson reported receiving a grant of 8,170 shares of restricted common stock. The award was recorded at a price of $0.00 per share, reflecting a stock-based compensation grant rather than an open-market purchase.
These shares were granted under the BioLife Solutions 2023 Performance Incentive Plan and, according to the terms, fully vest on the first anniversary of the vesting date of January 2, 2026. Following this grant, Ellingson directly holds a total of 57,995 shares of BioLife Solutions common stock.
BioLife Solutions President and CEO Roderick De Greef reported several equity awards and related tax withholdings. On February 24, 2026, he acquired three blocks of restricted common stock totaling 118,730, 170,291 and 219,024 shares at a stated price of $0.00 per share.
The awards were granted under the BioLife Solutions 2023 Omnibus Performance Incentive Plan, including 2026 compensation that vests 25% on the first anniversary and then in 12 equal quarterly installments. Other restricted stock vested based on total shareholder return from January 1, 2024 to December 31, 2025 versus peers and on specific performance metrics, leading to vesting at approximately 156% and 200% of target.
To satisfy tax withholding obligations on the market‑ and performance‑based vesting, 67,010 and 86,186 shares were disposed of at $22.65 per share through share withholding rather than open‑market sales. After these transactions, De Greef directly held 744,847 shares of BioLife Solutions common stock.
BioLife Solutions executive Mathew Aby J., EVP & Chief Scientific Officer, reported equity awards and related share withholding in company stock. He acquired 20,096 shares of restricted common stock and 39,605 shares of market-based restricted stock on February 24, 2026 at a stated price of $0.0000 per share.
The awards were granted under the BioLife Solutions 2023 Omnibus Performance Incentive Plan as part of 2026 compensation. One grant vests 25% on the first anniversary of the grant date and then in 12 equal quarterly installments. The market-based award vested at approximately 156% of the original grant based on relative total shareholder return versus selected peers from January 1, 2024 through December 31, 2025.
To cover tax withholding obligations on the vesting of the market-based award, 15,585 shares were withheld at $22.65 per share. Following these transactions, Mathew Aby J. directly owns 393,466 shares of BioLife Solutions common stock.
BioLife Solutions Chief Human Resources Officer Sarah Aebersold received a grant of 23,548 shares of common stock at $0.00 per share, tied to the company’s 2023 Omnibus Performance Incentive Plan. About 156% of the target shares vested based on relative total shareholder return, and 5,734 shares were withheld at $22.65 per share to cover taxes, leaving her with 93,579 shares directly owned.
Werner Sean reported acquisition or exercise transactions in this Form 4 filing.
BioLife Solutions Chief Technology Officer Sean Werner received a grant of 24,116 shares of common stock as part of his 2026 compensation. The restricted stock was issued under the 2023 Omnibus Performance Incentive Plan and will vest 25% on the first anniversary of the grant date, then in 12 equal quarterly installments. Following this award, he directly holds 50,043 shares of common stock.
MOORE TIMOTHY L. reported acquisition or exercise transactions in this Form 4 filing.
BioLife Solutions director Timothy L. Moore received a grant of 8,170 shares of restricted common stock. The award was made at a stated price of $0.0000 per share and was granted under the BioLife Solutions 2023 Performance Incentive Plan.
According to the filing, these restricted shares will fully vest on the first anniversary of the vesting date of January 2, 2026. After this grant, Moore directly holds a total of 44,943 shares of BioLife Solutions common stock.
BioLife Solutions executive Karen A. Foster reported equity compensation activity involving company common stock. She acquired 32,112 shares at no cost as a grant under the BioLife Solutions 2023 Omnibus Performance Incentive Plan. The restricted stock vested at approximately 156% of the target amount based on total shareholder return versus selected peers for the period from January 1, 2024 through December 31, 2025. In a related tax-withholding disposition, 13,013 shares were withheld at a price of $22.65 per share to cover tax obligations upon vesting. After these transactions, she directly held 211,083 shares of common stock.
GOSWAMI JOYDEEP reported acquisition or exercise transactions in this Form 4 filing.
BioLife Solutions Inc. director Joydeep Goswami received a grant of 8,170 shares of restricted common stock, recorded at a price of $0 per share as a stock award rather than a market purchase. Following this grant, his directly held common stock increased to 53,156 shares.
The restricted stock was granted under the BioLife Solutions 2023 Performance Incentive Plan and, according to the disclosure, will fully vest on the first anniversary of the vesting date of January 2, 2026.
BioLife Solutions Chief Financial Officer Troy Wichterman reported selling 990 shares of common stock on 01/06/2026 at $25.59 per share. Following this sale, he beneficially owned 150,746 shares.
The sale was executed under a pre-arranged Rule 10b5-1(c) trading plan adopted effective 01/03/2023 to satisfy tax withholding obligations arising from the vesting of restricted stock, indicating it was linked to equity compensation rather than a discretionary open-market exit.
BioLife Solutions Inc. executive Karen A. Foster, Chief Quality and Operations Officer, reported a small automatic sale of company stock. On 01/06/2026, she sold 335 shares of BioLife Solutions common stock at a price of $25.59 per share. After this transaction, she beneficially owned 191,984 shares of common stock directly. The sale was executed under a pre-arranged Rule 10b5-1(c) trading plan that became effective on 01/03/2023 and was used to cover tax withholding obligations tied to the vesting of restricted stock.
BioLife Solutions Inc. Chief Human Resources Officer Sarah Aebersold reported a small sale of company stock. On 01/06/2026, she sold 241 shares of Common Stock at a price of $25.59 per share, leaving her with 75,765 shares owned directly after the transaction.
According to the footnote, this sale was made under a Rule 10b5-1(c) trading plan that was adopted effective 01-03-2023. The filing explains that the trade was executed to satisfy tax withholding obligations related to the vesting of restricted stock rather than as a discretionary open-market sale.
BioLife Solutions executive Aby J. Mathew reported a small insider sale of company stock. On 01/06/2026, the EVP & Chief Scientific Officer sold 405 shares of BioLife Solutions common stock at a price of $25.59 per share. After this transaction, he directly held 349,350 shares of the company’s common stock.
The sale was made under a pre-arranged Rule 10b5-1(c) trading plan that became effective on 01/03/2023, and was carried out to satisfy tax withholding obligations arising from the vesting of restricted stock.
BioLife Solutions' Chief Marketing Officer reported a small insider sale of company stock. On 01/06/2026, Todd Berard sold 344 shares of BioLife Solutions common stock at a price of $25.59 per share, leaving him with 132,564 shares beneficially owned directly after the transaction.
According to the disclosure, this sale was made under a pre-arranged Rule 10b5-1(c) trading plan adopted effective 01/03/2023 and was executed to satisfy tax withholding obligations related to the vesting of restricted stock. This indicates the transaction was part of tax and compensation administration rather than a discretionary open-market sale.
BioLife Solutions Inc. executive vice president and chief scientific officer Aby J. Mathew reported a small insider sale of company stock. On 12/09/2025, he sold 631 shares of common stock at $25.13 per share. After this transaction, he directly owns 349,755 shares of BioLife Solutions common stock.
The filing states that this sale was executed under a pre-arranged Rule 10b5-1(c) trading plan, which was adopted effective 03-08-2024. The purpose of the plan was to sell shares to cover tax withholding obligations arising from the vesting of restricted stock, indicating this was an automated, tax-related transaction rather than a discretionary open-market sale.
BioLife Solutions Inc.'s Chief Financial Officer reported a sale of company stock under a pre-arranged Rule 10b5-1(c) trading plan. On 12/09/2025, the officer sold 1,033 shares of common stock at a price of $25.13 per share. After this transaction, the officer beneficially owned 151,736 shares of BioLife Solutions common stock in direct ownership. The filing explains that the sale was made to satisfy tax withholding obligations related to the vesting of restricted stock.
BioLife Solutions Inc. reported insider share sales by its Chief Human Resources Officer. The officer sold 233 shares of common stock on 12/09/2025 at $25.13 per share and 713 shares on 12/15/2025 at $24.46 per share. After these transactions, the officer beneficially owns 76,006 shares directly. The sales were made under a Rule 10b5-1(c) trading plan adopted effective 03-08-2024 to cover tax withholding obligations from the vesting of restricted stock.
BioLife Solutions Inc. director Amy DuRoss reported a sale of company stock. On 12/15/2025, she sold 2,000 shares of BioLife Solutions common stock at a price of $24.6 per share. After this transaction, she beneficially owned 18,687 shares, held directly.
BioLife Solutions Inc. reported an insider stock sale by its Chief Marketing Officer. On 12/09/2025, the officer sold 358 shares of common stock at a price of $25.13 per share. After this transaction, the officer beneficially owned 132,908 shares in a direct capacity.
The sale was made under a Rule 10b5-1(c) trading plan that the reporting person adopted effective 03-08-2024 to cover tax withholding obligations tied to the vesting of restricted stock. This indicates the transaction was pre-arranged for tax purposes rather than a discretionary open-market sale.
BioLife Solutions Inc. officer Karen A. Foster, Chief Quality and Operations, reported a small stock sale in a Form 4 filing. On 12/09/2025, she sold 519 shares of common stock at $25.13 per share. This transaction was made under a pre-arranged Rule 10b5-1(c) trading plan adopted effective 03-08-2024 to cover tax withholding obligations from the vesting of restricted stock. After this sale, she directly holds 192,319 shares of BioLife Solutions common stock.